C4 Therapeutics, Inc. 2024-2025 Proxy Voting Records

1. TO CAST A NON-BINDING, ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

C4 Therapeutics, Inc.’s own tally for this item (“b) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.”): 48,851,725 for, 889,711 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,007,083 outstanding shares: 69% for, 1% against (70% of the company cast a for/against vote).

The 105 asset managers below cast 99.1% of the shares they voted on this item FOR (49,029,149 for, 402,130 against).

Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.

2. To elect three Class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Donna Grogan, M.D.

Combines 3 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Donna Grogan, M.D.”): 42,592,170 for, 7,200,834 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,007,083 outstanding shares: 60% for, 10% withheld (70% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (9,683,455 for, 0 against).

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

3. To elect three Class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Ronald Harold Wilfred Cooper

Combines 3 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Ronald Harold Wilfred Cooper”): 38,963,561 for, 10,829,443 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,007,083 outstanding shares: 54.9% for, 15% withheld (70% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (9,833,515 for, 0 against).

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

4. To elect three Class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders and until his/her successor has been duly elected and qualified, or until his/her earlier resignation or removal: Steven Hoerter

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

C4 Therapeutics, Inc.’s own tally for this item (“Elect Director: Steven Hoerter”): 49,604,182 for, 188,822 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,007,083 outstanding shares: 70% for, 0.3% withheld (70% of the company cast a for/withheld vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (11,174,164 for, 0 against).

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

5. To approve an amendment to our Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000

Combines 2 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

C4 Therapeutics, Inc.’s own tally for this item (“d) The Company's stockholders approved the amendment to the Company's Fifth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000.”): 39,547,136 for, 20,664,896 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,007,083 outstanding shares: 56% for, 29% against (85% of the company cast a for/against vote).

The 37 asset managers below cast 85% of the shares they voted on this item FOR (9,576,592 for, 1,704,403 against).

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.

6. TO RATIFY THE ENGAGEMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

99.8% Majority: yes · of votes cast

C4 Therapeutics, Inc.’s own tally for this item (“c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 60,179,540 for, 79,871 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,007,083 outstanding shares: 85% for, 0.2% against (85% of the company cast a for/against vote).

The 37 asset managers below cast 100% of the shares they voted on this item FOR (11,280,995 for, 0 against).

Showing the 25 largest of 37 asset managers. See all 37 in the interactive database.